がん診断の日本市場2018

【英語タイトル】2018 Japan Cancer Diagnostics Market Segmentation Analysis: Hospitals, Commercial Labs--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Venture Planning Groupが出版した調査資料(VPMD807048)・商品コード:VPMD807048
・発行会社(調査会社):Venture Planning Group
・発行日:2018年6月29日
・ページ数:590
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:日本
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Local PDF(同一国内共有可)USD8,800 ⇒換算¥959,200見積依頼/購入/質問フォーム
Global PDF(複数国内共有可)USD19,740 ⇒換算¥2,151,660見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Complete report $8,800.  DataPack (test volumes, sales forecasts, supplier shares) $5,700.  The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget.

This new report from VPGMarketResearch.com is based on a study of the major business opportunities emerging in the Japanese cancer diagnostics market during the next five years. The report examines trends in the Japanese market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the Japanese cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Japanese Market Overview

- Five-year test volume and sales projections.
- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.
- Estimated universe of laboratories performing cancer diagnostic testing.
- Cancer statistics, etiology and recent developments in Japan.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Oncogenes
- Biochemical Markers
- Growth Factors
- Colony Stimulating Factors
- Hormones
- Immunohistochemical Stains
- Lymphokines

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers by individual test.

- Five-year test volume and sales forecasts for major tumor markers by market segment, including:

     º  Hospitals
     º  Commercial/Private Laboratories

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest technologies and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies.
- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

   – Abbott
   – AdnaGen
   – Agilent Technologies
   – Applied Gene Technologies
   – Arca Biopharma
   – Beckman Coulter/Danaher
   – Becton Dickinson
   – Biomedical Diagnostics
   – bioMerieux
   – Bio-Rad
   – CellSearch
   – Cepheid
   – Correlogic Systems/Vermillion
   – Decode Genetics
   – Diadexus
   – Diagnocure
   – DiaSorin
   – Eiken Chemical
   – Elitech Group
   – Enterix
   – Enzo Biochem
   – Epigenomics
   – Exact Sciences
   – Fujirebio
   – Guided Therapeutics
   – Hologic/Gen-Probe
   – Kreatech/Leica
   – Kyowa Medex
   – Mackay Life Sciences
   – Myriad Genetics
   – OncoLab
   – Ortho-Clinical Diagnostics
   – Panacea Pharmaceuticals
   – Polartechnics
   – Polymedco
   – PreMD
   – Qiagen
   – Quest Diagnostics
   – Radient Pharmaceuticals
   – Roche
   – Scienion
   – Sequenom
   – Siemens Healthcare
   – Takara Bio
   – Targeted Diagnostics & Therapeutics
   – Thermo Fisher
   – Tosoh
   – Veridex
   – Wako Pure Chemicals
   – Wallac/PE
   – Zila

Contains 590 pages and 95 tables

【レポートの目次】

※目次は次のURLでご確認いただけます。->http://www.vpgcorp.com/webfiles/CANCER/TOCLOTPartial%20MarketSegmentationAnalysisoftheJapaneseCancerDiagnosticsIndustry.pdf



【掲載企業】

http://www.vpgcorp.com/webfiles/CANCER/CancerCompanyProfiled.pdf

【レポートのキーワード】

がん診断

★調査レポート[がん診断の日本市場2018] (コード:VPMD807048)販売に関する免責事項を必ずご確認ください。
★調査レポート[がん診断の日本市場2018]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆